Exosome-Driven Cell Migration & Invasion Assays

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

Cell migration and invasion are among the most biologically consequential phenotypic readouts in exosome research—they underlie tumor metastasis, wound healing, immune cell trafficking, and tissue regeneration. Yet the effect of a microbial extracellular vesicle (mEV) preparation on these processes can range from potent promotion to complete suppression, depending on the vesicle source, cargo composition, concentration, and target cell context. At Creative BioMart Microbe, we provide standardized, quantitative migration and invasion assays that measure how your mEVs—whether tumor-derived OMVs, probiotic CMVs, or engineered therapeutic vesicles—modulate the motile and invasive behavior of target cells. Our platform integrates complementary assay formats, molecular endpoint analysis, and mechanism-focused experimental designs to deliver functional data with clear biological interpretation.

The key differentiator of our service is the microbial-native perspective we bring to every experiment. We account for these vesicle-type-specific biology in assay design, control selection, and data interpretation—ensuring that the migration or invasion phenotype you observe reflects genuine mEV bioactivity rather than assay artifact. Whether your goal is to screen engineered vesicle variants for anti-metastatic activity, validate probiotic mEV wound-healing efficacy, or characterize the pro-migratory potential of tumor-derived OMVs, our assays deliver the quantitative, reproducible data you need. Contact us to design a migration and invasion study for your mEVs.

Multi-stage scientific workflow diagram showing the exosome-driven cell migration and invasion assay pipeline from vesicle preparation through wound healing scratch assay, transwell migration/invasion, to molecular endpoint analysis including Western blot and qPCR for EMT markers.
Figure 1. Exosome-driven cell migration and invasion assay workflow spanning scratch wound healing, transwell migration and Matrigel invasion, and molecular endpoint analysis for EMT marker quantification.

Services

Service Workflow

Our migration and invasion assay workflow integrates phenotypic screening with molecular mechanism analysis, progressing from initial screening through quantitative endpoint measurement to mechanistic confirmation.

Five-step horizontal workflow showing Assay Design & Cell Preparation, mEV Treatment & Phenotypic Assay, Quantitative Image Analysis, Molecular Endpoint Profiling, and Integrated Data Reporting.

Inquiry

Service Details

3D illustration of a wound healing scratch assay showing a cell monolayer with a central scratch gap, with exosome-treated wells showing accelerated gap closure compared to untreated controls, overlaid with time-lapse closure curves.

Scratch Wound Healing Assay

We create standardized scratch wounds in confluent cell monolayers and track gap closure by time-lapse microscopy over a defined time course. mEV treatment groups are compared against untreated and positive controls. Automated image analysis quantifies wound area, closure rate, and percentage wound closure, generating kinetic curves that reveal both the magnitude and tempo of mEV effects on collective cell migration.

3D illustration of a transwell chamber system showing cells migrating through porous membrane pores toward a chemoattractant, with exosome-treated cells shown in teal passing through the membrane at a higher rate than untreated cells, with a crystal violet-stained membrane inset.

Transwell Migration & Matrigel Invasion Assays

Boyden chamber assays quantify directed cell migration through standard pore size membranes. For invasion assessment, membranes are coated with Matrigel basement membrane matrix, requiring cells to proteolytically degrade the extracellular matrix barrier to reach the lower chamber. Migrated or invaded cells are fixed, stained, and quantified by microscopy or colorimetric measurement. This format cleanly separates migration from proliferation effects.

3D illustration of tumor spheroids embedded in a collagen matrix, with exosome-treated spheroids showing elongated invasive strands extending outward compared to compact untreated spheroids, with quantification of invasion area and distance.

3D Spheroid Invasion Assay

For physiologically relevant invasion assessment, we embed multicellular tumor spheroids in collagen I or Matrigel matrices and measure radial invasion over an extended observation period. This 3D format captures cell-matrix interactions, collective invasion behavior, and protease-dependent matrix remodeling that 2D assays cannot replicate. mEV treatment effects on invasion area, maximum invasion distance, and invasive strand number are quantified by automated image analysis.

3D illustration of a Western blot membrane showing E-cadherin downregulation and N-cadherin/vimentin upregulation in exosome-treated cells compared to untreated, alongside a qPCR bar chart showing corresponding mRNA changes.

EMT Marker & Molecular Mechanism Profiling

Migration and invasion phenotypes are contextualized by molecular endpoint analysis. We measure epithelial-to-mesenchymal transition (EMT) markers by qPCR and western blot. Matrix metalloproteinase activity is assessed by gelatin zymography. For signaling pathway analysis, phospho-protein western blotting or pathway-specific reporter assays identify the upstream drivers of mEV-induced phenotypic changes.

3D illustration of a multi-well plate migration screening setup with different inhibitor conditions in each column, showing bar charts of wound closure rates under each condition, with specific pathway inhibitors highlighted.

Inhibitor-Based Pathway Dissection

We identify which signaling pathways mediate mEV-driven migration or invasion using selective pharmacological inhibitors. Standard panels target TGF-β receptor, PI3K/Akt, MEK/ERK, p38 MAPK, and NF-κB pathways. Inhibitor rescue experiments determine whether blocking a specific pathway abolishes or attenuates the mEV effect, providing actionable mechanistic information for therapeutic development or mechanism-of-action documentation.

Service Specifications & QC Standards

Instrumentation & Capability

Live-cell imaging: Automated time-lapse microscopy with environmental control for scratch assay monitoring.
Transwell systems: Standard Boyden chamber format with and without Matrigel coating.
3D spheroid culture: Ultra-low attachment plates for spheroid formation, embedded in collagen I or Matrigel matrices.
Image analysis: Automated wound area quantification and spheroid invasion measurement using ImageJ/Fiji and CellProfiler pipelines.
qPCR: Gene expression analysis for EMT and signaling pathway markers.
Western blot: Chemiluminescence detection with normalization to housekeeping proteins.
Gelatin zymography: MMP-2 and MMP-9 activity detection with densitometric quantification.

Typical Data Range

Scratch wound closure: Variable closure rates over time-course imaging (cell line and treatment dependent).
Wound closure rate precision: High reproducibility between replicate wells using standardized inserts.
Transwell migration: Dose-dependent migrated cell counts per field.
Matrigel invasion: Variable fold-difference vs. uncoated migration (cell line dependent).
3D spheroid invasion: Measurable invasion distance over multi-day culture.
EMT marker fold-change: Detectable mRNA and protein changes by qPCR and western blot.
MMP activity: Increased pro- and active MMP-2/MMP-9 bands by zymography.
Inhibitor rescue: Attenuation of mEV-induced migration/invasion by pathway-specific inhibitors.

Turnaround Time

Project Type	Timeline
Single scratch wound healing assay (dose–response)	1–2 weeks
Transwell migration assay (1 cell type, multiple conditions)	1–2 weeks
Matrigel invasion assay (1 cell type, multiple conditions)	1–2 weeks
Combined migration + invasion package	2–3 weeks
3D spheroid invasion assay	2–3 weeks
EMT marker profiling (qPCR + western blot)	1–2 weeks
Inhibitor pathway dissection panel	2–3 weeks
Comprehensive migration/invasion characterization package	4–6 weeks

Timelines may vary based on cell type, number of conditions, and assay complexity.

Deliverables

Scratch assay dataset: Time-lapse image sequences, wound area quantification, closure rate curves.
Transwell assay data: Stained membrane images, cell count quantification, statistical comparisons.
3D spheroid invasion data: Brightfield/fluorescence image stacks, invasion area and distance metrics.
qPCR data: Relative gene expression with statistical analysis for all tested markers.
Western blot images: Full uncropped blot images with densitometry quantification.
Gelatin zymography: Gel images with band intensity quantification for MMP-2 and MMP-9.
Inhibitor profiling report: Dose–response curves for each inhibitor, pathway attribution analysis.
Integrated report: Combined phenotypic and molecular data with biological interpretation.

Quality Control

Cell line authentication by STR profiling before assay initiation.
Mycoplasma testing on all cell cultures within 2 weeks of assay start.
Scratch insert uniformity: Low coefficient of variation in gap width across all wells.
Positive controls: Serum or specific growth factor stimulation confirming assay responsiveness.
Proliferation control: Parallel MTS/EdU assay quantifying any residual proliferation contribution.
LPS control: Polymyxin B-treated mEV controls for OMV preparations to isolate LPS-driven effects.
Biological triplicates for all phenotypic assays; technical duplicates for molecular endpoints.
Intra-assay and inter-assay CV within acceptable ranges for migration and invasion endpoints.

Sample Requirements

Required Information	Optional Information	Not Accepted
mEV source (microbial species, strain, OMV/CMV classification) Target cell type and expected effect direction (promotion or inhibition of migration/invasion) Prior vesicle characterization data (NTA size, protein concentration, TEM) Preferred assay format(s) (scratch, transwell, spheroid, inhibitor profiling) Number of mEV doses/concentrations to test Endotoxin level data (if known) for OMV preparations	Prior functional data (e.g., uptake efficiency, reporter gene results) Hypothesized signaling pathway involvement for targeted inhibitor selection Specific EMT or migration markers of interest Desired statistical power and replicate requirements Custom cell lines requiring establishment and validation	Uncharacterized vesicle preparations (no size or concentration data) Crude culture supernatants without vesicle enrichment Endotoxin-contaminated samples without mitigation documentation for cell-based assays Aggregated or degraded vesicle preparations Vesicle samples in culture media (interferes with assay media standardization) Samples shipped at ambient temperature

Recommended Sample Quantity by Assay:

Assay Type	Minimum	Recommended
Single scratch wound healing assay (3 doses)	20 μg total protein	40–60 μg total protein
Transwell migration assay (3 conditions)	15 μg total protein	30–50 μg total protein
Matrigel invasion assay (3 conditions)	15 μg total protein	30–50 μg total protein
3D spheroid invasion assay	30 μg total protein	60–100 μg total protein
EMT marker profiling (qPCR + western blot)	20 μg total protein	40–60 μg total protein
Inhibitor pathway dissection (5 inhibitors)	50 μg total protein	100–150 μg total protein
Comprehensive migration/invasion package	100 μg total protein	200–300 μg total protein

Storage & Shipping: Ship purified mEV suspensions in sterile PBS on dry ice. For OMV preparations, include LPS quantification data if available. Avoid freeze-thaw cycles; aliquot samples into single-use volumes before shipping when possible. For functional studies requiring intact vesicle bioactivity, we recommend coordinating with our Exosome Isolation & Purification Services team to arrange fresh preparation and direct transfer to the functional assay laboratory, minimizing storage time and preserving bioactivity.

Inquiry

Our Advantages

Multi-Format, Orthogonal Assay Design — Every project combines at least two complementary assay formats with cross-validated results, eliminating format-specific artifacts for robust mEV motility characterization.
Microbial Vesicle-Aware Control Strategy — OMV- and CMV-specific controls including polymyxin B-neutralized and TLR4 inhibitor conditions isolate true vesicle bioactivity from innate immune activation artifacts.
Phenotype-to-Mechanism Integration — Integrated EMT profiling, MMP analysis, and inhibitor-based pathway dissection transform phenotypic observations into actionable mechanistic narratives for publication and regulatory use.
3D Physiological Relevance — Spheroid invasion assays capture cell-matrix interactions and collective invasion behavior that 2D formats miss, providing translationally relevant data for therapeutic mEV development.
Proliferation-Adjusted Migration Metrics — Systematic deconvolution of migration and proliferation via proliferation arrest, parallel assays, and complementary formats delivers genuine migration rates free from cell division confounding.

Applications

3D icon showing tumor cells migrating away from a primary tumor mass, with exosomes being released and affecting migration behavior, tracked by a migration trajectory overlay.

Cancer Metastasis Mechanism Studies

Determine whether tumor-derived OMVs or engineered mEVs promote or suppress cancer cell migration and invasion in metastatic models.

3D icon showing a wound gap being closed by migrating cells under the influence of probiotic-derived vesicles, with time-lapse progression panels from open wound to complete closure.

Probiotic Wound Healing Validation

Quantify the wound-healing and tissue repair efficacy of probiotic mEVs for functional food, nutraceutical, and dermatological applications.

3D icon of a multi-well screening plate with different engineered vesicle variants being tested, showing a ranked bar chart of invasion inhibition with the top candidates highlighted.

Anti-Metastatic Drug & Vesicle Screening

Screen engineered or drug-loaded mEV libraries for their ability to inhibit tumor cell invasion, identifying lead candidates for further development.

3D icon of immune cells migrating through an endothelial barrier in response to chemokine gradients, with mEV treatment modulating the migration pattern shown by arrow trajectory changes.

Immune Cell Trafficking Modulation

Assess how mEVs affect the migration and chemotaxis of macrophages, neutrophils, or T cells in inflammatory and tumor microenvironment models.

Case Study

Case Study 1: Probiotic BEVs Accelerate Wound Healing via miR-21a-5p/PI3K/AKT

Researchers isolated BEVs from Lactobacillus reuteri and identified miR-21a-5p as the primary cargo via sequencing. Scratch and Transwell assays showed LR-BEVs significantly accelerated HUVEC and HaCaT migration and promoted angiogenic tube formation, effects abolished by miR-21a-5p inhibitor. Western blot confirmed PI3K/AKT pathway activation with increased p-AKT and HIF-1α. In diabetic mice, subcutaneous LR-BEVs treatment for 14 days expedited wound closure, re-epithelialization, and granulation tissue formation while mitigating inflammation, with no systemic toxicity. These results demonstrate probiotic BEVs functionally deliver miRNA cargo to activate wound-healing signaling pathways, validating mechanism-of-action characterization for microbial vesicles.

Figure 2. LR-BEVs transferring miR-21a-5p to promote the proliferation, migration, and angiogenesis of endothelial HUVEC in vitro. (Li, et al. 2025)

Case Study 2: Tumor-Derived OMVs Enhance OSCC Migration and Dysregulate Tumor Suppressors

Investigators examined Porphyromonas gingivalis OMV effects on oral squamous cell carcinoma (OSCC) migration. IHC confirmed elevated P. gingivalis abundance in OSCC tissues correlated with poor prognosis. Scratch and Transwell assays revealed 50 µg/mL OMVs significantly enhanced HN6 cell migration in a dose-dependent manner, while CAL27 cells showed no response, demonstrating cell-type specificity. RNA-seq and RT-qPCR identified consistent downregulation of tumor suppressor genes TNFSF15, ZNF292, and ATRX in both cell lines upon OMV treatment. These findings illustrate how pathogen-derived OMVs modulate cancer cell migration through cargo-mediated gene expression changes, underscoring the need for mechanism-focused assays with integrated molecular profiling to distinguish specific bioactivity from non-specific effects in microbial vesicle–cancer interactions.

Figure 3. P. gingivalis OMVs had no significant effect on the horizontal migration of CAL27 cells, but promoted the horizontal migration of HN6 cells. (Zeng, et al. 2025)

FAQs

Q: How do you separate the effect of mEVs on cell migration from their effect on cell proliferation in scratch assays?

A: We use a three-pronged approach. First, cells are pre-treated with mitomycin C to arrest proliferation before scratch wounding. Second, we run parallel MTS or EdU proliferation assays under identical mEV treatment conditions to quantify any residual proliferation contribution. Third, transwell migration assays (6–24 h duration) serve as a complementary format where the short time window inherently minimizes proliferation effects. We report proliferation-adjusted migration rates when any residual proliferation is detected.

Q: Do LPS and other bacterial components in OMV preparations cause non-specific migration effects?

A: They can, which is why we include dedicated controls. Polymyxin B pre-treatment neutralizes LPS and its TLR4-mediated signaling, allowing us to quantify the LPS-dependent vs. LPS-independent contribution to the observed migration phenotype. We also include TAK-242 (TLR4 inhibitor) conditions and, when appropriate, purified LPS dose-matched controls. For CMVs from Gram-positive probiotics, LTA-mediated effects are controlled using LTA-neutralizing antibodies or TLR2 inhibitors.

Q: What is the advantage of 3D spheroid invasion assays over standard 2D transwell assays?

A: 2D transwell assays measure the ability of individual cells to migrate through pores, which is a useful screening format but does not capture collective invasion behavior, cell-matrix adhesion dynamics, or protease-dependent matrix remodeling—all of which occur in tissue. 3D spheroid invasion embeds multicellular tumor masses in a physiologically relevant extracellular matrix environment, revealing invasion patterns (collective strands vs. single-cell dissemination), matrix degradation zones, and the depth of invasion that better predict in vivo behavior.

Q: Can you test mEV effects on both promotion and inhibition of migration in the same study?

A: Yes, and this is a common experimental design. Many projects compare the migration/invasion effects of multiple mEV types (e.g., tumor-derived OMVs vs. probiotic CMVs) or multiple engineered variants within the same cell type. We design the assay plate layout to include vehicle controls, positive controls (FBS or growth factor for migration promotion; migration inhibitor for suppression), and all mEV treatment groups in the same experimental run, enabling direct statistical comparisons.

Q: How do you determine whether mEV-induced migration changes are mediated through EMT or through other mechanisms?

A: Our standard molecular profiling panel measures canonical EMT transcription factors (Snail, Slug, Twist, ZEB1), epithelial markers (E-cadherin, ZO-1, cytokeratins), and mesenchymal markers (N-cadherin, vimentin, fibronectin) at both mRNA and protein levels. If EMT marker changes are detected, inhibitor-based pathway dissection identifies the upstream signaling drivers (typically TGF-β, Wnt, or Notch). If no EMT marker changes are observed despite a clear migration phenotype, we investigate alternative mechanisms including cytoskeletal reorganization (Rho GTPase activity), integrin switching, or chemokine receptor modulation.

Q: How do migration and invasion assays connect to the broader functional characterization workflow?

A: Migration and invasion assays are typically the phenotypic endpoint of a functional characterization cascade that begins with exosome uptake assays (confirming internalization) and reporter gene assays (confirming functional cargo delivery). The complete sequence—uptake → functional cargo delivery → migration/invasion phenotype—provides the strongest possible evidence for a causal relationship between mEV cargo and biological effect, supporting high-impact publication and regulatory filings.

References:

Li, Y., et al. (2025). Bacteria extracellular vesicles derived from Lactobacillus reuteri delivering intrinsic miR-21a-5p to accelerate diabetic wound healing. Nano Research, 18, 94908083.
Zeng, Y., et al. (2025). Porphyromonas gingivalis outer membrane vesicles augments proliferation and metastasis of oral squamous cell carcinoma cells. BMC Oral Health, 25, 701.

Services

Inquiry